Effect of once daily topical 0.3% naltrexone on tear parameters and corneal sensitivity in dogs with uncontrolled keratoconjunctivitis sicca: a double-masked randomized placebo-controlled clinical trial.

Abstract

OBJECTIVE: To determine the effect of once daily topical 0.3% naltrexone (NTX) on tear production, tear film breakup time (TFBUT), and corneal sensitivity in dogs with uncontrolled keratoconjunctivitis sicca (KCS). ANIMALS STUDIED: Sixteen dogs with uncontrolled KCS. PROCEDURES: A randomized placebo-controlled trial was performed in 16 dogs with topical 0.3% NTX once daily or topical saline solution drops once daily. A baseline was obtained at week 0 for tear production (Schirmer tear test 1 and 2-STT1, STT2), TFBUT, and corneal sensitivity. STT1, STT2, and TFBUT were then subsequently measured at weeks 1, 2, and 4 while on NTX or saline drops. Corneal sensitivity measures were repeated at week 4. The drops were subsequently discontinued and all parameters rechecked at week 5. RESULTS: There was no statistically significant difference in tear parameters or corneal sensitivity between the NTX-treated and the saline-treated groups. CONCLUSION: Topical 0.3% NTX given as a once daily dose over 4 weeks did not alter tear production, tear film stability, or corneal sensitivity in dogs with uncontrolled KCS.